Evolent Health, Inc. (NYSE:EVH) Shares Bought by Sterling Capital Management LLC

Sterling Capital Management LLC raised its position in Evolent Health, Inc. (NYSE:EVH - Free Report) by 36.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,344 shares of the technology company's stock after acquiring an additional 28,424 shares during the quarter. Sterling Capital Management LLC owned approximately 0.09% of Evolent Health worth $1,196,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Evolent Health by 1.0% in the 3rd quarter. State Street Corp now owns 2,725,375 shares of the technology company's stock valued at $77,074,000 after purchasing an additional 25,967 shares in the last quarter. Barclays PLC raised its position in Evolent Health by 181.3% in the 3rd quarter. Barclays PLC now owns 273,776 shares of the technology company's stock valued at $7,742,000 after purchasing an additional 176,445 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of Evolent Health by 40.8% during the third quarter. Franklin Resources Inc. now owns 909,776 shares of the technology company's stock worth $24,682,000 after buying an additional 263,815 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Evolent Health by 268.0% in the 3rd quarter. Principal Financial Group Inc. now owns 57,382 shares of the technology company's stock valued at $1,623,000 after purchasing an additional 41,788 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Evolent Health by 7.0% in the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company's stock valued at $1,469,000 after buying an additional 8,552 shares during the period.

Evolent Health Stock Performance

NYSE:EVH traded down $0.34 during trading hours on Monday, reaching $8.62. 145,823 shares of the stock were exchanged, compared to its average volume of 2,321,160. The stock has a market capitalization of $1.01 billion, a P/E ratio of -10.53 and a beta of 1.20. The firm has a 50 day simple moving average of $9.64 and a 200-day simple moving average of $13.10. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 52 week low of $8.35 and a 52 week high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.35). The company had revenue of $646.54 million for the quarter, compared to analyst estimates of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. As a group, sell-side analysts forecast that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

EVH has been the topic of a number of recent analyst reports. Truist Financial dropped their price objective on Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Oppenheimer reduced their price objective on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research note on Friday, February 21st. JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a report on Monday, March 10th. Finally, Canaccord Genuity Group decreased their target price on Evolent Health from $23.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $17.64.

Insider Activity at Evolent Health

In related news, Director Diane Holder bought 2,735 shares of the stock in a transaction on Thursday, March 6th. The shares were purchased at an average price of $9.33 per share, with a total value of $25,517.55. Following the purchase, the director now owns 70,584 shares in the company, valued at approximately $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Seth Blackley purchased 55,225 shares of Evolent Health stock in a transaction dated Thursday, March 6th. The stock was bought at an average cost of $9.01 per share, with a total value of $497,577.25. Following the completion of the purchase, the chief executive officer now owns 762,217 shares in the company, valued at approximately $6,867,575.17. This trade represents a 7.81 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 74,000 shares of company stock worth $666,315 over the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.